AdΔEP–TETP

AdΔEP–TETP appears to be a recombinant adenoviral vector described in the literature as an engineered oncolytic virus. The "AdΔEP" refers to an adenovirus backbone with deletions in the E1 and/or E3 regions (commonly used for tumor specificity and safety), and "TETP" is likely a tumor-targeting peptide or genetic element designed to enhance tumor selectivity or oncolytic potency. This vector is generally designed for intratumoral injection to achieve selective replication in, and lysis of, cancer cells while sparing normal tissues. These vectors are often investigated in preclinical cancer gene therapy and immunotherapy models. Specific developer, manufacturer, or late-phase clinical trial information is not available in public regulatory and pharmaceutical databases. Mechanistic information may relate to oncolytic virotherapy, immunogenic cell death, and possibly delivery of tumor-targeted genetic cargo.